2.1
80
Bouchahda M, Macarulla T, Spano JP, Bachet JB, Lledo G, Andre T, Landi B, Tabernero J, Karaboué A, Domont J, Levi F, Rougier P. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol 2008; 67 (3): 255-62. FI: 4,632
Boyle P, Anderson BO, Andersson LC, Ariyaratne Y, Auleley GR, Barbacid M, Bartelink H, Baselga J, Behbehani K, Belardelli F, Berns A, Bishop J, Brawley O, Burns H, Clanton M, Cox B, Currow D, Dangou JM, Valeriola D de, Dinshaw K, et al. Need for global action for cancer control. Ann Oncol 2008; 19 (9): 1519-21. FI: 4,875
Briasoulis E, Pavlidis N, Felip E; ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii106-7. FI: 4,875
Brunet J, Gutiérrez-Enríquez S, Torres A, Bérez V, Sanjosé S, Galcerán J, Izquierdo A, Menéndez JA, Gumà J, Borràs J. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations. Clin Genet 2008; 73 (5): 465-73. FI: 3,181
Callejas-Valera JL, Guinea-Viniegra J, Ramírez-Castillejo C, Recio JA, GalánMoya E, Martínez N, Rojas JM, Cajal SR, Sánchez-Prieto R. E1a gene expression blocks the ERK1/2 signaling pathway by promoting nuclear localization and MKP up-regulation: implication in v-H-Ras-induced senescence. J Biol Chem 2008; 283 (19): 13450-8. FI: 5,581
Capdevila J, Elez E, Peralta S, Macarulla T, Ramos FJ, Tabernero J. Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Rev Anticancer Ther 2008; 8 (8): 1223-36. FI:1,988
Caralt M, Bilbao I, Cortés J, Escartín A, Lázaro JL, Dopazo C, Olsina JJ, Balsells J, Charco R. Hepatic Resection for Liver Metastases as Part of the «Oncosurgical» Treatment of Metastatic Breast Cancer. Ann Surg Oncol 2008; 15 (10): 2804-10. FI: 3,917
Carracedo A, Baselga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008; 7 (24). FI: 3,314
Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118 (9): 3065-74. FI: 16,915
Àrea 1. Oncologia i genètica
Chan AT, Felip E; ESMO Guidelines Working Group. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol 2008; 19 (Suppl 2): ii81-2. FI: 4,875 Cosimo S di, Baselga J. Targeted therapies in breast cancer: Where are we now? Eur J Cancer 2008; 44 (18): 2781-90. FI: 4,454
Cutsem E van, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, Gramont A de, Diaz-Rubio E, Ducreux M, Goldberg R, GlynneJones R, Haller D, Kang YK, Kerr D, Labianca R, Tabernero J, et al. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol 2008; 19 (Suppl 6): vi1-8. FI: 4,875
Domingo E, Suriñach JM, Murillo J, Durán M, Suriñach J, Baselga J, Sevilla TF de. Prognostic factors in the diagnostic work-up of cancer patients in an internal medicine department: does age matter? Int J Clin Pract 2008; 62 (11): 1723-9. FI: 1,594
Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzmán M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68 (22): 9221-30. FI: 7,672